PeakShares LLC Invests $506,000 in Pfizer Inc. $PFE

PeakShares LLC acquired a new position in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 20,307 shares of the biopharmaceutical company’s stock, valued at approximately $506,000.

A number of other institutional investors and hedge funds have also bought and sold shares of PFE. Union Savings Bank bought a new stake in shares of Pfizer in the 4th quarter valued at about $296,000. Gunpowder Capital Management LLC dba Oliver Wealth Management acquired a new stake in shares of Pfizer in the fourth quarter valued at about $50,000. Mengis Capital Management Inc. raised its position in shares of Pfizer by 12.3% during the fourth quarter. Mengis Capital Management Inc. now owns 64,213 shares of the biopharmaceutical company’s stock worth $1,599,000 after acquiring an additional 7,056 shares during the last quarter. Bayban acquired a new position in shares of Pfizer in the fourth quarter worth approximately $114,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Pfizer in the fourth quarter worth approximately $2,555,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reaffirmed its 2026 guidance and said its strategic outlook remains intact, which should help limit downside if investors focus on fundamentals rather than the management change. Pfizer stock slides following CFO exit, 2026 guidance reaffirmed
• Positive Sentiment: The company moved quickly to appoint an interim finance chief, suggesting Pfizer has a planned transition process in place rather than a broader disruption to operations. Pfizer Announces Chief Financial Officer Transition
• Neutral Sentiment: News coverage also noted that Pfizer’s recent move is part of a broader investor debate about the company’s near-term growth catalysts and pipeline execution, rather than a change to its core business outlook. Reuters coverage of CFO departure
• Negative Sentiment: The biggest overhang is the unexpected departure of the CFO, which can create uncertainty about financial discipline and near-term investor confidence, helping explain why PFE has been declining. Pfizer CFO to leave company for consumer goods role

Analysts Set New Price Targets

A number of research firms have weighed in on PFE. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, June 13th. CICC Research initiated coverage on shares of Pfizer in a research report on Thursday, April 16th. They issued an “outperform” rating and a $33.00 price target on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a research note on Monday, June 1st. UBS Group reissued a “neutral” rating and set a $27.00 target price on shares of Pfizer in a research note on Wednesday, May 27th. Finally, Royal Bank Of Canada upgraded shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price on the stock in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $28.82.

Pfizer Trading Up 0.2%

NYSE PFE opened at $25.25 on Friday. The stock has a market capitalization of $143.94 billion, a P/E ratio of 19.28 and a beta of 0.34. The business has a 50 day simple moving average of $26.22 and a 200 day simple moving average of $26.33. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. Pfizer Inc. has a one year low of $23.11 and a one year high of $28.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.03. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Research analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, June 12th. Investors of record on Friday, May 8th were paid a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.8%. Pfizer’s dividend payout ratio is currently 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.